SOHO 2023 | Multiple myeloma: elranatamab as a single-agent therapy compared to CAR-T therapy
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the recent FDA approval of elranatamab for patients with multiple myeloma, and highlights the advantages associated with this agent compared to CAR-T therapy. Dr Lin also comments on ongoing studies investigating the use of this antibody in combination with other agents and the potential to use measurable residual disease (MRD) to direct elranatamab treatment in the future. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bluebird Bio: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Gamida Cell: Consultancy; Takeda: Research Funding; Vineti: Consultancy; Sorrento: Consultancy; Merck: Research Funding.
